In an attempt to lower the risk of acute GVHD we used CD34 marrow cell selection for T cell depletion. Since T cell depletion has been linked to an increased risk of relapse and an increased risk of marrow failure, we used PCR amplification of minisatellite sequences to investigate donor cell engraftment and RT-PCR amplification of recurrent chromosomal translocations to investigate the residual disease post-transplant. Twenty-three patients who underwent BMT after positive selection of the CD34-positive cell population were studied. Results were then compared with those of 37 patients who underwent transplantation with unmanipulated marrow graft. Among the 23 patients who received CD34
Introduction
Although allogeneic bone marrow transplantation (BMT) is now accepted as a treatment option that can provide a cure for patients with leukaemia, bone marrow failure syndromes and congenital disorders, this type of treatment was until recently limited to patients with an HLA-identical sibling donor. Recently, to extend haematopoietic cell transplantation to patients who could benefit from an allogeneic marrow transplant, but who lack a suitable HLA-matched related donor, the use of other sources of haematopoietic stem cells (marrow, cord blood or peripheral blood) from partially HLAmatched family members or unrelated donors has been explored worldwide. Among these stem cell sources, bone marrow is still the most widely used. However, in several studies unrelated marrow transplantation has been linked with significant problems, including a high incidence of acute and chronic graft-versus-host disease (GVHD) and of graft failure. [1] [2] [3] [4] [5] [6] [7] In parallel, it has also been suggested that the use of an unrelated donor may be associated with a decreased risk of relapse of the underlying malignant disease. 3 In an attempt to lower the risk of acute GVHD we used CD34 marrow cell selection for T cell depletion. Since T cell depletion has been linked with an increased risk of relapse and an increased risk of marrow failure, we used PCR amplification of minisatellite sequences to investigate donor cell engraftment and RT-PCR amplification of recurrent chromosomal translocations to investigate the residual disease post-transplant. Twenty-three patients who underwent BMT after positive selection of the CD34-positive cell population were studied. Results were then compared with those of 37 patients who underwent transplantation with an unmanipulated marrow graft.
Patients and methods

Patients and transplant characteristics
In February 1995, we began a phase I-II trial, using the Baxter Isolex 300 device (Baxter, Irvine, CA, USA) of CD34-positive cell selection as a means of T cell depletion of the marrow graft to reduce the incidence of acute GVHD. The results of this phase I-II trial will be the subject of a separate article. The clinical characteristics of the 23 patients who underwent BMT after positive selection of the CD34-positive cell population and those of the 37 patients who underwent unmanipulated BMT are summarized in Table 1 . Age, gender distribution, diagnosis and stage of the diseases were similar in both groups. However, conditioning regimen and GVHD prophylaxis clearly differed. In the first group, the conditioning regimen and the GVHD prophylaxis varied during the time period and according to the initial diagnosis. For example, patients who received low-dose cyclophosphamide and thoraco-abdominal irradiation had Fanconi's anaemia and patients who received the TAMe regimen had lymphoid malignancies. Ten patients received monoclonal antibodies (anti-IL2 receptor in nine patients and anti-LFA1 in a single case), as part of phase II-III studies. In contrast, patients who received CD34 + selected cell transplants, were delivered more homogeneous conditioning regimens, ie the association of fractionated total body irradiation, cyclophosphamide, thiotepa and anti-thymocyte globulins (ATG) in patients with haematological malignancies and low-dose single fraction TBI (4.5 Gy), low-dose cyclophosphamide and ATG for patients with Fanconi's anaemia.
Donor-recipient matching
Serologic testing was performed using a standard microlymphocytotoxicity method. Generic HLA-DRB1 and DQB1 typing were performed using the INNO-LIPA DRB and DQB test (Immogenetics, Zwijnaarde, Belgium). For patients and selected donors, HLA-DRB1, B3 and B5 high resolution typing was performed by PCR amplification using sequence-specific primers combined with restriction fragment-length polymorphism (RFLP). HLA-DPB1 subtyping was performed using either PCR-RFLP or the INNO-LIPA DP kit. Results of HLA matching between donor and recipient are summarized in Table 2 .
Methods
Chimaerism study:
A peripheral blood sample from each recipient (and whenever possible from the donor) was collected before transplantation and then at least once after transplantation. Genomic DNA was extracted either from whole blood samples or after lymphocyte and polymorphonuclear cell separation, 8 the latter technique being used provided that enough nucleated cells could be collected (ie no attempt was made to separate the lymphocyte and polymorphonuclear cells if the total white blood cell count was below 1 × 10 9 /l. PCR amplification of minisatellite sequences 33.6.3 and MS51 was performed as previously described. 9 If donor-recipient pairs were non-informative at the 33.6.3. and MS51 loci, patients were studied at the YNZ22 locus. 10 After PCR amplification, samples were analysed by Southern blotting and hybridization 8 with probes labelled by random priming (Amersham Megaprime and DNA labeling system; Amersham, Les Ullis, France). Quantification of the results was achieved with a Bioimaging Analyser BAS 1000 and the MacBas 2.2 software (Fuji Photo Film Co., Japan). Patients were considered to have a mixed chimaerism when both the donor and the recipient's specific alleles were demonstrable after hybridisation. In our hands, the sensitivity limit of this technique is between 0.1 and 1%.
8-10
RT-PCR amplification of the BCR-ABL and AML1-ETO fusion transcripts for the evaluation of the minimal residual disease post-transplant:
Total RNA was extracted from cryopreserved cells. The quality and quantity of RNA were controlled on an ethidium bromide stained 1% agarose gel containing . After an initial denaturation step of 3 min at 94°C, 34 cycles consisting of 1 min at 94°C, 1 min at 58°C and 1 min at 72°C followed by a final extension of 10 min at 72°C were performed in a DNA thermal cycler (GeneAmp PCR System 9600; Perkin Elmer Cetus, Montigny le Bretonneux, France). For all the RNA samples, amplification of the ABL mRNA was performed as an internal control from a common cDNA. The oligonucleotides used for PCR amplification of the reverse transcribed fusion transcripts were the following:
• BCR-ABL transcripts: MBCR: CMLA and CMLB primers; mBCR: ALLE and ALLF according to previously published oligonucleotide sequences. 11 Since July 1996, we used CMLX instead of CMLA and since December 1996 CMLB was used instead of ALLF. The sequence of CMLX is as follows: 5′ CAGATGCTGACCAACTGCTGT 3′ • AML1-ETO transcripts: AML1-C and MTG8-2, as described by Kozu et al 12 • Abelson transcripts: abl1 (2nd exon) 5′ CCTTCAGCGGCCAGTAGCATCTGAC 3′; and abl2 (3rd exon) 5′ GGACACAGGCCCATGGTACCAGGAG 3′.
To assess the sensitivity of each RT-PCR experiment, total RNA extracted from either the K562 cell line (BCR-ABL detection) or an AML1-ETO-positive diagnosis sample and Kasumi-1 cell line (AML1-ETO detection) was serially diluted in RNA extracted from normal peripheral blood mononuclear cells of SW620 cells (from 1 to 10 −5 ). One microgram of diluted RNAs was then submitted to RT-PCR. Samples were analysed at least twice and two negative controls were included in each experiment. PCR products were run on a 3% NuSieve (FMC BioProducts, Rockland, ME, USA) 1% agarose gel, transferred to a Hybond N+ membrane (Amersham International, UK) and hybridized to 30 ng of an internal oligonucleotide probe labelled with T4 polynucleotide kinase in the presence of 10 Ci ␥ 32 P-ATP (New England Biolabs, Beverly, MA, USA). The internal probe used for the detection of the BCR-ABL PCR products was described by Pignon et al 11 and the internal probe used for AML1-ETO PCR product analysis had the following sequence: 5′ GAGTGCTTCTCAGTACGAT 3′. Negative PCR results were defined by the absence of any visible PCR product, after amplification and autoradiography in an up to 10 −5 sensitive assay.
Results
Chimaerism Study Patients grafted with CD34
+ selected cells: Among the 23 patients who received CD34
+ selected cell grafts, seven (30%) had evidence of full donor engraftment, within the sensitivity limit of the method.
Fourteen patients (61%) had evidence of residual recipient cells at some points during follow-up. All but two patients with insufficient follow-up had at least two analyses of their chimaerism profile post-transplant. Among these 14 patients with a mixed chimaerism profile, six were also studied for the presence of minimal residual disease and are described in detail in the next section. Eight other patients had mixed chimaerism. The level of mixed chimaerism, its evolution in each patient, and the blood cell population(s) in which the analyses have been done (DNA from whole blood or after lymphocytes and polymorphonuclear separation) is summarized in Table 3 . Patient UPN 1089 with MDS had a progressive mixed profile and subsequently died of late marrow failure during viral infection. The four patients with Fanconi's anaemia are alive 13, 10, 9 and 7 months post-transplant. The two patients with AML are alive and in complete haematological remission 10 and 8 months post-transplant. Finally, the patient with ALL had evidence of residual recipient cells at 4 and 5 months and subsequently relapsed (UPN 1080).
The analysis of post-transplant DNA showed a non-take (recipient profile) in one patient whose initial diagnosis was MDS (UPN 978). One patient with CML (UPN 1106) did not engraft and was given a back-up autologous marrow. The autologous bone marrow recovery was confirmed by molecular analysis.
Patients grafted with an unmanipulated marrow:
Among the 37 patients in this situation, 36 were analysed for chimaerism status. One patient with CML (UPN 740) was searched for the presence of minimal residual disease early after transplantation. He was BCR-ABL negative but died shortly after, before the analysis of the chimaerism status could be performed.
Thirty-one patients (86%) had evidence of full donor engraftment. Two patients (6%) had evidence of residual recipient cells (one with CML, and one with AML). One of these patients (UPN 764) also had evidence of persistent bcr-abl fusion transcript and died of relapse 15 months post-transplant. The other one (patient UPN 963) died of severe pancytopenia following acute GVHD (the estimate of residual recipient cell on a whole blood sample was 5%). The difference in the incidence of mixed chimaerism profile between patients who received an unmanipulated marrow graft (2/36 (6%)) and those receiving CD34
+ selected cell grafts (14/23 (61%)) is statistically significant (P Ͻ 0.01 by Fisher's exact test).
The analysis of post-transplant DNA showed a non-take (recipient profile) in two patients whose initial diagnoses were CML and paroxysmal nocturnal hemoglobinuria, respectively. One patient with ALL had evidence of rejection (low level of donor type cells followed by a complete recipient profile type).
Minimal residual disease study Patients grafted with CD34
+ selected cells:
The results of MRD and of chimaerism studies, performed post-transplant in nine patients, are summarized in Figure 1 . The patient transplanted for a t(9;22) (b3a2) ALL (UPN 1070) had no evidence of MRD, until the last follow-up. Eight patients with t(9;22)-positive CML were evaluated. In all of them, the BCR-ABL fusion transcript had been characterized pretransplant (five had a b2a2 and three a b3a2 fusion transcript). In two of these eight patients, the search for a fusion transcript was consistently negative after transplantation. It is worth noting that these two patients with no evidence of residual disease in the short term (8-10 months post-transplant), had by the same time a mixed chimaerism profile strongly suggesting the persistence of non-leukaemic recipient cells post-transplant. One patient (UPN 1106) with CML who did not engraft and was given a back-up autologous marrow had obvious evidence of residual disease since autologous bone marrow recovery was proven. Three patients had repeated evidence of both residual disease and mixed chimaerism. Those three patients were given donor lymphocyte infusion (DLI) at a mean of 9 months post-transplant. Two out of the three patients were evaluable following DLI. They were both free of detectable residual disease. Finally, one patient (UPN 1092) had a donor type profile at 3 and 6 months but, while being bcr-abl negative at 3 months, became positive at 6 months.
Figure 1
Chimaerism and minimal residual disease after CD34-positive selected cell transplantation. In cases of mixed chimaerism and of detected residual disease, the percentage of recipient cells and the level of bcr-abl fusion transcript are indicated in parentheses. Since the proportion of residual recipient cell did not vary significantly between the lymphocyte and the polymorphonuclear cell fractions only the average percentage of mixed chimaerism is provided in parentheses.
Patients grafted with an unmanipulated marrow:
The results of MRD and of chimaerism studies, performed posttransplant in 16 patients, are summarized in Figure 2 . Fourteen patients with t(9;22)-positive CML were evaluated. In six of them the BCR-ABL fusion transcript was characterized pretransplant. For 10 of these 14 patients (71%), the search for a fusion transcript was consistently negative after transplantation. From the data of CML patients who received a CD34 cell graft this is not statistically significant but clearly warrants more patients with longer follow-up to be studied. One patient (UPN 661) had a positive search for a b3a2 transcript posttransplant but died of a transplant-related cause (unrelated to CML) shortly thereafter. Patient UPN 764 had mixed chimaerism and MRD was consistently detected. He subsequently relapsed in acute transformation. Of note, is the case of patient UPN 825 who had a repated donor type profile (three time points) and who had a long-lasting untreated molecular relapse (without cytogenetic relapse).
Discussion
Since the advent of molecular biology techniques, the number of studies which address the chimeric status of patients transplanted for leukaemia or non-malignant disease has increased (see review in Ref. 13 ). However, to the best of our knowledge, only one joint study by the Dublin and Bristol groups was specifically aimed at following the chimaerism status of young patients with ALL who underwent allogeneic BMT from a volunteer unrelated donor.
14 On the other hand, while RT-PCR-based detection of the BCR-ABL transcripts has now became the gold standard technique for residual disease detection post-transplant, published data often include in the same study patients who were transplanted from HLAidentical siblings and patients grafted from an unrelated donor. [15] [16] [17] Furthermore, only two studies were aimed at looking for both chimaerism status and residual disease of patients after marrow transplantation for CML. [18] [19] [20] Finally, interpretation of chimaerism data and residual disease studies is also dependent on whether the graft has been T cell depleted or not.
In contrast to the study by Molloy and co-workers 14 that specifically looked at chimaerism status in patients with ALL, this study involved patients with various diagnoses who received various conditioning therapies. The population under study represents the whole consecutive cohort of transplants from unrelated donors who could be evaluated during the time period. Two cohorts of patients were compared, one that received CD34
+ selected cell marrow graft and one that was delivered an unmanipulated marrow graft.
Our analysis of post-transplant chimaerism showed either a non-take (recipient profile) in four patients or evidence of rejection in one patient. This is in sharp contrast to our previous study on patients transplanted with HLA-identical sibling donors, but is in accordance with the increased risk of engraftment failure or the higher rejection rate reported after unrelated transplantation. [1] [2] [3] [4] [5] Four patients with Fanconi's anaemia were shown to have residual recipient cell post-transplant following CD34 cell transplantation. We previously described such a pattern of mixed chimaerism in a patient with Fanconi's anaemia after transplantation from an HLAidentical sibling donor. 9 Our results might suggest that the pattern of engraftment in Fanconi's anaemia patients is similar after transplantation with either an unrelated or an HLA-identical sibling donor. However, the study of additional Fanconi's patients transplanted from unrelated donors with CD34 marrow cell is clearly needed. There was a statistically significant difference in the incidence of mixed chimaerism between patients who received unmanipulated marrow graft and those receiving CD34
+ selected cell grafts, overall. Since the method used for CD34
+ cell selection leads to a 2-3 log T cell depletion (data not shown), it is likely that the difference in the incidence of mixed chimaerism in these two cohorts of patients is reminiscent of the higher incidence of mixed chimaerism after T cell depletion as compared to unmanipulated transplantation (reviewed in Ref. 13 ). It has previously been suggested that there is a relationship between the occurrence and severity of GVHD and the incidence of mixed chimaerism (reviewed in Ref. 13 ). In fact, using CD34
+ selection as a means of T cell depletion, not only was the incidence of mixed chimaerism higher but also the incidence of severe acute GVHD was lower (20% grade II-IV) in patients receiving CD34
+ selected cell grafts as compared to more than 60% in those who received unmanipulated marrow graft.
Concerning MRD and its relationship with chimaerism status, our results differed in the two cohorts. In 10 out of the 14 CML patients grafted with an unmanipulated marrow, and in two of eight patients with CML grafted with CD34 selected cells, the search for a fusion transcript was consistently negative after transplantation. However, while after unmanipulated marrow transplant these bcr-abl-negative patients had a donor-type profile, the two patients who received a CD34 cells graft had a mixed chimaerism profile. Since PCR amplification of minisatellite sequences is a much less sensitive technique than the highly sensitive PCR amplification of the leukaemia-specific fusion transcript, our results strongly suggest the persistence of non-leukaemic recipient cells posttransplant following the newer approach. One patient who received an unmanipulated graft had constant detection of MRD and mixed chimaerism and subsequently relapsed in acute transformation with complex cytogenetic abnormalities. This profile of dual persistence of MRD and mixed chimaerism status fits with that previously reported by Mackinnon and coworkers. 20 However, it should be stressed that 30/32 patients included in Mackinnon's study received a T cell-depleted transplant and that the predictive value for leukaemic relapse of the dual detection of MRD and mixed chimaerism may vary depending on whether or not the patient receives a T cell-depleted bone marrow. This difference in terms of chimaerism and residual disease status between T cell and non T celldepleted transplant recipients with CML is in accordance with a recent study by Gardiner and co-workers 21 on 22 patients grafted from an HLA-identical sibling donor. Three patients who were grafted with CD34
+ selected cells and who were bcr-abl positive also had a low level of residual recipient cells. They were then given a donor-leucocyte fusion and progressed to a complete donor-type profile with disappearance of detectable MRD. Thus, since CD34
+ cell selection leads to noticeable T cell depletion, the relationship between chimaerism and MRD (and subsequent risk of relapse) after CD34 + cell transplantation requires further assessment on a larger number of patients. In contrast to these latter cases were the evolution of two patients (one who received an unmanipulated marrow and the other a CD34
+ cell selected graft) who had a repeated donor-type profile in chimaerism studies but who exhibited a molecular relapse (without cytogenetic relapse) that has been untreated to the present time. In a recent study 22 involving 52 patients with CML and transplanted from an unrelated donor, Drobyski et al 22 showed that at least one positive PCR assay was predictive for subsequent haematological relapse of the disease. All these 52 patients received a T cell-depleted transplant. Thus, while we do agree that PCR positivity might be predictive of relapse, we would like to underline the usefulness of assessing the chimaerism status of such patients. Whether or not the graft has been manipulated should also be taken into consideration before discussing the use of donor leucocyte infusion. Finally, some studies 23, 24 relied on quantitative methods to evaluate posttransplant the number of bcr-abl transcripts. These analyses have demonstrated that patients destined to relapse generally have an increasing number of detectable transcripts. Although we did not accurately quantitate bcr-abl transcript numbers, the assay we employed did permit a semi-quantitative assessment of disease burden and the results obtained were consistent with these previous studies. All patients with t(9;22) ALL and t(8;21) AML had a full donor-type profile with no evidence of residual disease, but no firm conclusions could be drawn from this study due to the small number of cases studied.
In conclusion, this study highlights the higher nontake/rejection rate after unrelated BMT as compared to our previous study in patients who underwent transplantation from an HLA-identical sibling donor, and the strong influence of graft manipulation on the incidence of mixed chimaerism after transplant from an unrelated donor. This study also underscores the complex inter-relationships between MRD and chimaerism.
